We have completed a third-party allotment of capital. While aiming to increase the number of N-NOSE tests and improve the consultation rate, we will promote our business with the immediate goal of putting the next-generation cancer type specific tests into practical use.
TOKYO, JAPAN – March 6, 2026 – HIROTSU Bio Science Inc. announced the establishment of a new U.S. subsidiary, Hirotsu Global Inc., effectively c . . .
2026.03.06FOR IMMEDIATE RELEASE HIROTSU Bio Science Announces Referral of Former Employee to Prosecutors for Violation of the Unfair Competition Preven . . .
2026.02.05A novel, non-invasive approach to detecting micro-distant metastasis in highly lethal pancreatic cancer. TOKYO, JAPAN – January 5, 2026 – HIR . . .
2026.01.05